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Abstract
Aim: Deregulation of FOXM1 has been documented in various cancers. The aim of this study was to evaluate the role of
FOXM1 in ovarian cancer tumorigenesis and paclitaxel resistance.
Experimental Design: Expression of FOXM1 was examined in 119 clinical samples by immunohistochemistry and correlated
with clinicopathological parameters. Effects of FOXM1 knockdown on ovarian cancer cell migration, invasion and mitotic
catastrophe were also studied. qPCR and ChIP-qPCR were used to establish KIF2C as a novel FOXM1 target gene implicated
in chemoresistance.
Results: High nuclear FOXM1 expression in ovarian cancer patient samples was significantly associated with advanced
stages (P= 0.035), shorter overall (P= 0.019) and disease-free (P= 0.014) survival. Multivariate analysis confirmed FOXM1
expression as an independent prognostic factor for ovarian cancer. FOXM1 knockdown significantly inhibited migration and
invasion of ovarian cancer cells and enhanced paclitaxel-mediated cell death and mitotic catastrophe in a p53-independent
manner. Bioinformatics analysis suggested a number of potential transcription targets of FOXM1. One of the potential
targets, KIF2C, exhibited similar expression pattern to FOXM1 in chemosensitive and chemoresistant cells in response to
paclitaxel treatment. FOXM1 could be detected at the promoter of KIF2C and FOXM1 silencing significantly down-regulated
KIF2C.
Conclusion: Our findings suggest that FOXM1 is associated with poor patient outcome and contributes to paclitaxel
resistance by blocking mitotic catastrophe. KIF2C is identified as a novel FOXM1 transcriptional target that may be
implicated in the acquisition of chemoresistance. FOXM1 should be further investigated as a potential prognostic marker
and therapeutic target for ovarian cancer.
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Introduction
Ovarian cancer is the most lethal gynaecological cancer
worldwide as most patients, when diagnosed, are presented with
advanced disease [1]. Although improvement in median survival
has been observed in recent decades, relapse and mortality rates
remain high due in part to the acquisition of chemoresistance [2].
A combination of paclitaxel and carboplatin has widely been used
as the first-line chemotherapy for ovarian cancer patients.
Paclitaxel acts specifically during the G2-M phase of the cell cycle
by inducing abnormal spindles and disruption of microtubule
dynamics, thereby blocking cell cycle progression. Despite its
initial effectiveness as a cancer therapeutic agent, in most cases,
patients eventually become insensitive to paclitaxel-based chemo-
therapy and relapse. It is therefore vital to identify novel
prognostic markers and therapeutic targets, particularly genes
related to metastasis and drug resistance.
Forkhead box (FOX) proteins belong to a superfamily of
evolutionarily conserved transcription factors responsible for the
spatio-temporal fine-tuning of a broad repertoire of transcriptional
programmes which are required for the normal homeostasis and
development [3]. Among which, forkhead box protein M1
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(FOXM1) participates in a wide range of biological processes
including cell proliferation, cell cycle progression, cell differenti-
ation, DNA damage repair, tissue homeostasis, angiogenesis and
apoptosis [4,5]. It is therefore not surprising that deregulation of
FOXM1 could result in severe pathological conditions, including
cancer. Indeed, FOXM1 overexpression has been documented in
cancers of the lung, breast, liver, prostate and colon, etc.
suggesting that FOXM1 has a key role in tumorigenesis [3,6].
Recently, it has been shown that deregulated FOXM1 expression
can confer resistance to chemotherapeutic drugs, such as cisplatin
and epirubicin, by protecting cells against DNA-damage induced
cell death, and disrupting the mitotic checkpoint [7–9].
In this study, we investigated the expression pattern of FOXM1
in ovarian cancer. The effects of FOXM1 expression on cancer
cell migration, invasion and paclitaxel resistance were also studied
in an attempt to evaluate FOXM1 as a potential molecular
prognostic marker and therapeutic target for ovarian cancer.
Further analyses were performed to identify KIF2C as a novel
FOXM1 transcriptional target that might be implicated in the
acquisition of chemoresistance.
Materials and Methods
Clinical samples and cell lines
Archival paraffin embedded tissue blocks from year 1987 to
2004 were retrieved from the Department of Pathology, Queen
Mary Hospital, the University of Hong Kong. The samples
included 2 benign cystadenomas, 2 borderline tumours, 94
primary carcinomas and 21 metastatic foci of cancer (at ligament,
gut, lymph node and uterine serosa). All patients with carcinoma
underwent surgery followed by the standard first-line chemother-
apy including platinum/paclitaxel. The follow-up period ranged
from 5 to 209 months (median 63 months). The use of these
samples was approved by the Institutional Ethical Review Board.
Each patient sample was assessed by pathologists and ensured to
contain more than 70% tumour cells.
Ovarian cancer cell lines SKOV-3 and OVCAR-3 were
purchased from American Type Culture Collection (Manassas,
VA, USA). SKOV3-TR cells were a generous gift from Dr
Lawrence XF Le (Division of Cancer Medicine, University of
Texas M.D. Anderson Cancer Center, Houston, Texas, USA)
[10]. PEO1 and PEO1-TaxR are recently developed cell lines and
have been authenticated at Cancer Research UK facility. The use
of PEO1 and PEO1-TaxR instead of SKOV-3 and SKOV3-TR
for some experiments offers extra means to ensure that resistant
mechanisms identified in SKOV-3 and SKOV3-TR are common
to all paclitaxel resistant ovarian cancer cells and not unique to
SKOV-3 and SKOV3-TR. Importantly, both PEO1 and PEO1-
TaxR are kept to lower passages to avoid drifts in resistance and
the acquisition of secondary mutations [10] [11]. OVCAR-3 was
cultured in 1:1 Medium 199 (Invitrogen, CA, USA): MCDB105
(Sigma, MO, USA) supplemented with 10% foetal bovine serum
(FBS) and 100 units/ml penicillin-streptomycin (Invitrogen).
SKOV3, SKOV3-TR, PEO1 and PEO1-TaxR were cultured in
RPMI1640 (Sigma) supplemented with 10% foetal bovine serum
(FBS) and 100 units/ml penicillin-streptomycin (Invitrogen).
PEO1-TaxR was supplemented with 50 nM paclitaxel. All cell
lines were maintained at 37uC in humidified incubator with 5%
CO2. Cell culture medium was changed every 3 to 5 days
depending on cell density. For routine passage, when cells reached
85% to 90% confluency, they were split at a ratio of 1:4.
Immunohistochemistry
Immunohistochemistry was performed as described previously
[12,13]. Briefly, formalin-fixed paraffin sections were incubated
with anti-FOXM1 antibody (NBP1-30961, 1:40, Novus Biologi-
cals, CO, USA) at room temperature overnight and stained using
EnVision+ Dual Link System (K4061; Dako, CA, USA). Antigen
retrieval was performed using EDTA buffer, pH8.0, in a pressure
cooker for 30 min. All sections were assessed by two independent
investigators. The immunoreactivity of FOXM1 antibody, the
intensity of stained cells and their percentages were measured in
terms of intensity and percentage scores respectively. The
percentage score ranged from 0 to 4: 0 =,5% of positively
stained cells, 1 = 5–25% of positively stained cells, 2 = 26–60% of
positively stained cells, 3 = 61–85% of positively stained cells, and
4= 86–100% of positively stained cells. Immunohistochemical
(IHC) score (from 0 to 16) was calculated by multiplying the
intensity score (0–4) and the percentage score (0–4), with a
maximum score of 16 [12,13]. FOXM1 nuclear and cytoplasmic
immunoreactivities were scored separately.
Western blot
Cells were harvested with lysis buffer [0.125 m Tris, pH 6.8 at
22uC containing 1% NP-40 (v/v), 2 mM ethylenediamine
tetraacetic acid (EDTA), 2 mM N-ethylmaleimide, 2 mM phe-
nylmethanesulphonyl fluoride (PMSF), 1 mM sodium orthovana-
date and 0.1 mm sodium okadate] and centrifuged at 4uC for
Table 1. Composition of buffers used in ChIP.
Buffer Composition
Buffer I 0.25% Triton X-100, 10 mM EDTA, 0.5 nM EGTA, 10 mM HEPES pH6.5
Buffer II 200 mM NaCl, 10 mM EDTA, 0.5 mM EGTA, 10 mM HEPES pH6.5
Buffer III 0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCL pH8.1
Lysis buffer 1% SDS, 10 mM EDTA, 50 mM Tris-HCL pH8.1
Buffer D 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCL pH8.1, 150 mM NaCl
TSE I 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCL pH8.1, 150 mM NaCl
TSE II 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCL pH8.1, 500 mM NaCl
TE buffer 10 mM Tris-HCL pH8.0, 1 mM EDTA
Scrapping buffer 100 mM Tris-HCL pH9.4, 0.1% SDS
Elution buffer 0.1 M NaHCO3, 1% SDS
doi:10.1371/journal.pone.0113478.t001
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10 min. Protein concentration was determined by detergent-
compatible (DC) protein assay (Bio-Rad). Twenty micrograms of
protein were separated by sodium dodecyl sulphate-polyacryl-
amide gel electrophoresis (SDS-PAGE), transferred to polyvinyli-
dene difluoride membrane and hybridized with the following anti-
bodies: anti-FOXM1 (sc-502, Santa Cruz Biotechnology, CA,
USA), anti-Caspase 9 (9502, Cell Signaling Technology, MA,
USA), anti-KIF2C (WH0011004M1, Sigma), anti-Caspase 7
(9492, Cell Signaling) and anti-b-tubulin (sc-9104, Santa Cruz
Biotechnology).
Quantitative real-time PCR
Quantitative real-time PCR (qPCR) was performed using
Power SYBR Green PCR Master Mix (Applied Biosystems) and
analysed by ABI7900 Sequence Detection System (Applied
Biosystems). L19 (RPL19), a non-regulated ribosomal housekeep-
Figure 1. Elevated nuclear FOXM1 expression was associated with advanced stages of ovarian cancer. A, Representative images of
immunoreactivity of nuclear FOXM1 in (I) benign cystadenoma, (II) borderline tumour, (III) stage I invasive cancer, (IV) stage II invasive cancer, (V)
stage III invasive cancer and (VI) stage IV invasive cancer. Magnifications X400. Insets: Regions with higher magnifications of nuclear FOXM1 staining.
B, Cumulative overall and disease-free survival plots using the Kaplan-Meier approach.
doi:10.1371/journal.pone.0113478.g001
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ing gene was used as an internal control for normalization using
the delta-delta Ct method. The following primers were used:
KIF2C Forward 59 to 39: CATGATTGCCACGATCTCAC
KIF2C Reverse 59 to 39: CGTTAGAGCAGGCTTCCATC
L19 Forward 59 to 39: GCGGAAGGGTACAGCCAAT
L19 Reverse 59 to 39: GCAGCCGGCGCAAA
Transient knockdown of FOXM1
ON-TARGET Plus Human FOXM1 siRNA and Non-target-
ing Control siRNAs (Thermo Scientific, CO, USA) were
employed for transient silencing of FOXM1 using Oligofectamine
Figure 2. Silencing of FOXM1 reduced migration and invasion of SKOV-3. A. Representative images showing cells migrated (gelatin-coated
membrane) or invaded (matrigel-coated membrane) after 24 h. B. Representative Western blot analysis demonstrating the effectiveness of FOXM1
transient knockdown in SKOV-3. C. Graphic representation of migration (left panel) and invasion (right panel) results as fold change of migrated and
invaded cells relative to the control, respectively, in five fields of triplicate wells from three independent experiments; * P,0.05, significant; Mann-
Whitney U-test.
doi:10.1371/journal.pone.0113478.g002
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transfection reagent (Invitrogen) as per the manufacturer’s
instructions.
In Vitro migration and invasion assays
In Vitro migration and invasion assays were performed as
described previously [12,13]. Briefly, 1.256105 cells were plated
on the upper compartment of a Transwell chamber (Corning Life
Sciences, MA, USA). For migration assays, cells were allowed to
migrate through a gelatin-coated membrane. For invasion assays,
cells were allowed to invade through a matrigel-coated membrane.
After 24 h, cells on the upper side of the membrane were removed
and the migrated or invaded cells were fixed, stained and counted.
TdT-mediated dUTP nick end labeling (TUNEL) assay and
evaluation of mitotic catastrophe index
Following FOXM1 knockdown for 48 h and paclitaxel treat-
ment (50 nM) for 24 h, TUNEL assay was performed using In
Situ Death Detection Kit (Roche Biochemical, IN, USA) following
the manufacturer’s protocol [14]. Apoptotic and mitotic catastro-
phe figures were assessed under fluorescence microscopy. Mitotic
catastrophe figures were observed by morphological changes in
nuclei (DAPI staining) [10]. More than 1000 viable cells in each
experiment were examined and the mitotic catastrophe index was
evaluated as percentages of the cells counted. Every assay was run
in triplicate.
Cell cycle analysis
Cell cycle analysis was performed by propidium iodide staining
as described previously [15]. Briefly, both adherent and suspension
cells were harvested and stained with propidium iodide (1 mg/mL)
in the presence of DNase-free RNase for flow cytometric analysis.
Cell cycle profile was analyzed by using the Cell Diva software
(Becton Dickinson UK Ltd.).
Chromatin Immunoprecipitation
40 ml of Dynabeads Protein A (10002D, Invitrogen) was washed
with 200 ml of TSE I buffer for three times and diluted with 40 ml
of TSE I buffer. Anti-FOXM1 (sc502, Santa Cruz Biotechnology)
(4 mg) and rabbit IgG control (X0903, DAKO) (4 mg) were first
separately diluted in Buffer D, mixed with diluted Dynabeads and
then rotated O/N at 4uC. PEO1 and PEO1-TaxR cells at 90%
confluency in 100 mm culture dish were crosslinked with 1%
formaldehyde for 10 min, rinsed with ice-cold PBS and incubated
with 2.5 M glycine for 5 min. Cells were then harvested with 2 ml
of scrapping buffer. After a sequential wash with PBS, Buffer I and
Buffer II, cell pellet was resuspended in 300 ml of Lysis buffer and
subjected to sonication under optimized condition (20 min with
30 s on and 30 s off). Supernatant was then diluted in 300 ml of
Buffer D from which 100 ml was taken as INPUT control. 200 ml
of cell lysate was mixed with prepared Dynabeads and rotated O/
N at 4uC. After a sequential wash with TSE I, TSE II, Buffer III
and TE buffer, 100 ml of elution buffer was added to the
Dynabeads and the mixture was rotated at RT for 1 h. Eluted
sample was collected in eppendorf and the Dynabeads was re-
eluted with another 100 ml of elution buffer. 200 ml of sample was
de-crosslinked by incubating at 65uC O/N. PCR Purification Kit
(Qiagen) was then used to purify DNA. Quantitative real-time
PCR was performed with the following primers: KIF2C (Forward
59 to 39: GCCAAGTCTCCAACTTGCTC; Reverse 59 to 39:
TTCCCAACCATCTTCCTACG).
ChIP-qPCR data was normalized to IgG control and plotted as
percent input. Composition of buffers was listed in Table 1.
Statistical analysis
Statistical analysis was performed by the Statistical Package for
Social Science version 19.0 for Windows (IBM). Comparison
between two groups of non-parametric data was performed by
Mann-Whitney U-test. Probability of survival was analyzed using
the Kaplan-Meier approach. Multivariate analysis of prognostic
factors was performed using Cox’s regression model. P-values of,
0.05 were considered to be statistically significant.
Results
FOXM1 overexpression correlates with poor survival
The expression of nuclear FOXM1 in ovarian benign and
borderline tumours as well as invasive cancers was evaluated by
immunohistochemistry. Ovarian cancers displayed stronger nu-
clear FOXM1 staining than benign and borderline tumours.
However, there was no significant difference in FOXM1
expression between primary carcinomas and their metastatic foci
(P=0.6). Higher nuclear FOXM1 expression was significantly
associated with advanced stages of ovarian cancer (P=0.035)
(Fig. 1A). Although not reaching statistical significance, FOXM1
overexpression displayed a trend related to serous histological type
(P=0.142), high grade cancers (poor differentiation) (P=0.235)
and chemoresistance (P=0.282) (Table 2). In order to study the
association of FOXM1 expression with patients’ outcome, patients
were categorized into two groups using the cutoff point of IHC
score.0. As shown in the Kaplan-Meier overall survival plot
(Fig. 1B), patients with negative FOXM1 staining had a signifi-
cantly longer overall (P=0.019) and disease-free survival
(P=0.014) than those with positive FOXM1 expression. Multi-
variate progression analysis showed high expression of FOXM1,
advanced cancer stages and poor histological differentiation (high
grade) were found to be independent prognostic factors for short
overall survival (95% CI, 0.906–5.754, HR 2.283, P=0.08; 95%
CI, 0.953–5.963, HR 2.384, P=0.06; 95% CI, 2.137–40.638, HR
9.318, P=0.003, respectively) and disease-free survival (95% CI,
1.025–6.631, HR 2.607, P=0.04; 95% CI, 1.039–6.555, HR
2.61, P=0.04; 95% CI, 1.821–35.091, HR 7.993, P=0.006,
respectively). Interestingly, cytoplasmic staining of FOXM1 was
also detected in addition to nuclear expression, but no significant
correlation with clinicopathological parameters was observed (data
not shown).
Figure 3. Paclitaxel treatment down-regulates FOXM1 expres-
sion in SKOV-3 but not in SKOV3-TR cells. The paclitaxel sensitive
SKOV-3 and resistant SKOV3-TR ovarian cancer cells were treated with
100 nM paclitaxel and harvested at times indicated for Western blot
analysis. Paclitaxel treatment down-regulated FOXM1 expression at
time points 48 h and 72 h in SKOV-3 but not in SKOV3-TR as shown by
immunoblotting. There were also no marked changes in the cleaved
Caspase-9 and Caspase-7 expression.
doi:10.1371/journal.pone.0113478.g003
FOXM1, Ovarian Cancer
PLOS ONE | www.plosone.org 6 November 2014 | Volume 9 | Issue 11 | e113478
Transient knockdown of FOXM1 inhibits SKOV-3 cell
migration and invasion
We next studied the role of FOXM1 in ovarian cancer
progression. In Vitro Transwell assays were employed to study
the effects of transient silencing of FOXM1 on ovarian cancer cell
motility and invasion. Significantly decreased migration and
invasion (P,0.05) was observed in SKOV-3 cells transfected with
ON-TARGET Plus Human FOXM1 siRNA (siFOXM1) as
compared to cells transfected with control siRNA (siControl),
indicating that knockdown of FOXM1 was capable of inhibiting
migration and invasion of SKOV3 cells (Fig. 2).
Paclitaxel treatment downregulates the expression of
FOXM1 in SKOV-3 but not in the paclitaxel-resistant
SKOV3-TR
In view of the IHC staining showing that elevated FOXM1
expression is associated with poor prognosis and thus chemore-
sistance, a pair of established ovarian cancer cell line sensitive and
Figure 4. Transient FOXM1 knockdown significantly enhanced paclitaxel-induced mitotic catastrophe in SKOV-3 and OVCAR3 cells.
SKOV-3 and OVCAR3 cells transfected with either siRNA pools against FOXM1 or control siRNA pools were treated with paclitaxel (100 nM) and
stained with DAPI. A. Representative staining results were shown showing that transient FOXM1 knockdown significantly enhanced paclitaxel-
induced mitotic catastrophe (arrow) in SKOV-3 and OVCAR3 cells respectively (Upper panel). B. Graphs represent the results of three independent
experiments, showing the percentage of cells undergoing mitotic catastrophe, * P,0.05, significant; Mann-Whitney U-test.
doi:10.1371/journal.pone.0113478.g004
FOXM1, Ovarian Cancer
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resistant to paclitaxel, namely SKOV-3 and SKOV3-TR respec-
tively, were used to study the effect of paclitaxel treatment on the
expression of FOXM1. Cells were treated with paclitaxel
(100 nM) and harvested at various time points 0, 8, 16, 24, 48
and 72 h. Intriguingly, immunoblotting showed FOXM1 expres-
sion to be decreased at 48 h and 72 h in SKOV-3. However,
FOXM1 expression remained relatively constant at high levels in
SKOV3-TR upon paclitaxel treatment (Fig. 3), suggesting a role
of FOXM1 in mediating paclitaxel resistance in ovarian cancer
cells. Notably, there also appeared to be only marginal increases in
the expression of cleaved Caspase-9 and Caspase-7 in both
SKOV-3 and SKOV3-TR upon paclitaxel treatment, suggesting
that apoptosis may not be the predominant mechanism of
inducing cell death in these ovarian carcinoma cells.
Transient silencing of FOXM1 significantly enhances
paclitaxel-mediated mitotic catastrophe
We previously showed that paclitaxel kills ovarian cancer cells
predominantly by inducing mitotic catastrophe rather than
apoptosis in the cells [10]. To elucidate the potential role of
FOXM1 in ovarian cancer chemoresistance, SKOV-3 and
OVCAR3 ovarian cancer cell lines were treated with paclitaxel
for 24 h following FOXM1 depletion by siRNA, stained with
DAPI and examined by fluorescent microscopy. The result
showed there was an increased number of multi-nucleated cells
(arrow) in ovarian cancer cells with FOXM1 knockdown (P=0.03
and 0.01, respectively) (Fig. 4), suggesting FOXM1 depletion
significantly enhanced paclitaxel-mediated mitotic catastrophe in
both SKOV-3 and OVCAR3. It is notable that apoptosis was
barely detectable in these paclitaxel-treated cells. This was
probably due to the fact that both SKOV-3 and OVCAR3
Figure 5. Flow cytometric analysis of SKOV-3 and SKOV-3-TR cells with and without FOXM1 depletion in the presence or absence of
paclitacel treatment. A. Flow cytometric analysis was performed following propidium iodide staining on SKOV-3 and SKOV-3-TR cells treated with
paclitaxel (100 nM) or remained untreated after transfection with siRNA pools against FOXM1 or control siRNA pools. Representative data are shown
indicating that FOXM1 silencing is capable of increasing the number of dead cells and cells blocked at G2/M cell cycle phase in SKOV-3-TR as
compared to cells treated with control siRNA. B. Bar charts of different phases of cell cycle in SKOV-3 and SKOV3-TR treated with paclitaxel after
transfection with control or siRNA against FOXM1. Results represent data from two independent experiments.
doi:10.1371/journal.pone.0113478.g005
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harbour dysfunctional p53, and functional p53 is required for
paclitaxel-induced apoptosis in ovarian cancer cells.
FOXM1 knockdown induces modest increases in the
accumulation of G2/M and dead cells upon paclitaxel
treatment in the resistant SKOV3-TR cell line
Cell cycle analysis was then performed to elucidate the role of
FOXM1 in paclitaxel-mediated cell death. To this end, SKOV-3
and SKOV3-TR cells were transiently transfected with control
and FOXM1 siRNA for 48 h and cultured in the presence or
absence of paclitaxel treatment (100 nM) for 48 h. The resultant
cells were harvested, stained with propidium iodide and subjected
to flow cytometric analysis. The results showed that paclitaxel
induced significant levels of cell death (sub-G1 population) in
SKOV-3 cells transfected with either FOXM1 or control siRNA
pool (Fig. 5A, upper panel). Increased number of cells accumu-
lated with sub-G1 DNA contents in SKOV3-TR with FOXM1
knockdown (8.1%) (Fig. 5A, upper panel) compared to SKOV3-
TR transfected with control siRNA (4.2%) (Fig. 5A, upper panel),
suggesting FOXM1 contributes to paclitaxel resistance in ovarian
cancer cells and that FOXM1 silencing can enhance paclitaxel-
mediated cell death. Upon paclitaxel treatment, a modest increase
in cells blocked at G2/M phase was also observed in SKOV3-TR
treated with siRNA against FOXM1 as compared to control,
suggesting FOXM1 silencing might enhance paclitaxel-mediated
cell death via mitotic catastrophe (Fig. 5A, lower panel; Fig. 5B).
Depletion of FOXM1 in the sensitive SKOV-3 cells has no
additive effect to paclitaxel treatment. This is likely due to the fact
that paclitaxel functions through downregulating FOXM1 expres-
sion as revealed by the Western blot analysis (see Fig. 3).
Figure 6. Identification of KIF2C as a novel FOXM1 transcriptional target that might be implicated in the acquisition of paclitaxel
resistance. A, Paclitaxel treatment (50 nM) down-regulated FOXM1 and KIF2C expressions at 48 h and 72 h in PEO1 but not in PEO1-TaxR. B,
FOXM1 knockdown significantly reduced the transcript level of KIF2C in PEO1 and PEO1-TaxR. Data represent triplicates from three experiments.
*P = 0.04, ***P = 0.0003. siControl: Non-specific control. siFOXM1: FOXM1 knockdown. C, ChIP-qPCR showed FOXM1 significantly pull down KIF2C
promoter region in PEO1 and PEO1-TaxR as compared to the negative IgG control. Data represent triplicates from three experiments. *P = 0.04,
***P = 0.0001. D, Schematic diagram depicting locations of forkhead response element (FHRE) and the binding site of primers used in ChIP-qPCR
upstream of the transcription start site of KIF2C.
doi:10.1371/journal.pone.0113478.g006
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KIF2C is identified as a novel FOXM1 transcriptional
target that may be implicated in the acquisition of
chemoresistance
Bioinformatics analysis revealed KIF2C, a member of the KIF
superfamily of proteins, as a potential target gene of FOXM1 with
consensus forkhead binding sites located upstream of the
transcription start site (Fig. 6D). Using a pair of paclitaxel-sensitive
(PEO1) and -resistant (PEO1-TaxR) ovarian cancer cell line,
paclitaxel treatment down-regulated the expression of KIF2C at
48 h and 72 h in PEO1. However, KIF2C expression remained
relatively constant in PEO1-TaxR upon paclitaxel treatment
(Fig. 6A), suggesting a role of KIF2C in mediating paclitaxel
resistance in ovarian cancer cells. Intriguingly, the expressions of
FOXM1 changed in a similar pattern (Fig. 6A). Quantitative real-
time PCR (qPCR) was then used to study the effect of transient
silencing of FOXM1 on the transcript level of KIF2C. FOXM1
knockdown resulted in significantly down-regulated mRNA
expressions of KIF2C in both cell lines (P,0.05) (Fig. 6B).
Chromatin immunoprecipitation-qPCR (ChIP-qPCR) further
showed FOXM1 was capable of binding to the promoter region
of KIF2C (P,0.05) (Fig. 6C), implying KIF2C might serve as a
novel FOXM1 transcriptional target.
Discussion
In this study, we show that high nuclear FOXM1 expression is
significantly correlated with stage, shorter overall survival and
disease-free survival of ovarian cancer patients. Multivariate
analysis indicates that FOXM1 expression could serve as an
independent prognostic factor. Furthermore, transient FOXM1
depletion is capable of inhibiting ovarian cancer cell migration.
These findings suggest that FOXM1 can have a crucial role in
ovarian carcinogenesis and progression and may predict patients’
outcome.
Although FOXM1’s association with high grade ovarian
carcinomas has been reported [16], whether FOXM1 participates
in the acquisition of paclitaxel resistance remains undefined.
Indeed, deregulated FOXM1 expression has been shown to confer
resistance to chemotherapeutic drugs such as cisplatin and
epirubicin [8,9]. In view of the immunohistochemical finding
suggesting association between FOXM1 and chemoresistance, a
pair of established paclitaxel-sensitive and -resistant cell lines,
SKOV-3 and SKOV3-TR [10], were employed to study the effect
of paclitaxel on FOXM1. Interestingly, paclitaxel treatment
resulted in down-regulation of FOXM1 in SKOV-3 but not in
the resistant cell line SKOV3-TR, implying a role of FOXM1 in
mediating paclitaxel resistance in ovarian cancer cells. Immuno-
fluorescence study further showed transient FOXM1 knockdown
could enhance paclitaxel-mediated cell death in two ovarian
cancer cell lines, SKOV-3 (deleted p53)[17] and OVCAR3
(mutant p53) [18]. It is not surprising that apoptotic cells were
barely detectable as both cell lines harbour dysfunctional p53.
Recently, it was suggested that the induction of p53-independent
apoptosis takes place through the activation of Caspase-9 [19].
However, immunoblotting revealed Caspase-9 was not activated
upon paclitaxel treatment in SKOV-3 and SKOV-3-TR cells,
indicating that both paclitaxel and FOXM1 silencing effect cell
death primarily through enhancing mitotic catastrophe rather
than apoptosis in ovarian cancer cells, which commonly have
dysfunctional p53 pathway. This is consistent with previous
findings on paclitaxel in breast cancer [20].
Mitotic catastrophe can be considered as a type of cell death
occurring during mitosis or resulting from mitotic failure [21].
Two mechanisms have been suggested as crucial for mitotic
catastrophe, namely the G2/M and mitotic spindle checkpoints
[22]. For the G2/M checkpoint, the inactivation of genes such as
p53, p21Cip1 and 14-3-3Sigma have been reported to induce
DNA damage-induced mitotic catastrophe [23,24]. Flow cytomet-
ric analysis performed in our study suggested FOXM1 knockdown
in the chemoresistant ovarian cancer cell line SKOV3-TR could
induce cell death. Paclitaxel treatment and immunofluorescent
analysis further suggested FOXM1 silencing could enhance
paclitaxel-mediated mitotic catastrophe in a p53-independent
and Caspase-9-independent manner. Delineation of the underly-
ing mechanism by which FOXM1 mediates paclitaxel resistance
will shed light on novel approaches of treatment.
Kinesin superfamily proteins (KIFs) play pivotal roles in
intracellular transport of organelles and maintenance of spindle
assembly during mitosis and meiosis [25]. Being the founding and
best-characterized member of the kinesin-13 family, KIF2C/
MCAK is crucial for ensuring the faithful segregation of
chromosomes in mitosis and for safeguarding chromosomal
stability [26]. Not surprisingly, up-regulations of KIF2C have
been documented in multiple human cancers and KIF2C has been
suggested to play an important role in carcinogenesis [27,28]. In
the current study, immunoblotting analysis showed KIF2C
expression in PEO1 altered in a similar pattern as FOXM1
expression by displaying a down-regulation at 48 h and 72 h upon
paclitaxel treatment. In contrast, KIF2C expression remained
relatively constant in PEO1-TaxR, implicating KIF2C might be
involved in the development of paclitaxel resistance in ovarian
cancer. This finding is consistent with a recent report demon-
strating loss of KIF2C could increase the sensitivity of Chinese
hamster ovary (CHO) cells to paclitaxel [29]. Furthermore,
KIF2C was identified as a novel FOXM1 transcriptional target
that might play a pivotal role in mediating paclitaxel resistance in
ovarian cancer cells.
In conclusion, overexpression of FOXM1 was found to be
correlated with poor patients’ survival and to paclitaxel-mediated
mitotic catastrophe in ovarian cancer cells. KIF2C was identified
as a novel FOXM1 target gene implicated in the mediation of
paclitaxel resistance. Our findings help to define FOXM1 as a
potential prognostic marker as well as a therapeutic target in
ovarian cancer.
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